Buy, Sell, Or Hold LLY Stock At $750?
Portfolio Pulse from
Eli Lilly's stock (LLY) dropped over 6% due to slower than expected growth in obesity drug sales, leading to a downward adjustment in Q4 revenue forecast by 5% to $13.5 billion, missing analysts' expectations.
January 15, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly's stock fell over 6% after the company announced slower than expected growth in obesity drug sales, leading to a 5% reduction in its Q4 revenue forecast to $13.5 billion, which is $500 million below analysts' expectations.
The stock price of Eli Lilly is likely to be negatively impacted in the short term due to the announcement of slower growth in obesity drug sales and a significant downward revision of its Q4 revenue forecast, which fell short of analysts' expectations by $500 million.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100